A Study to Test the Effect of Cyclosporine on the Immune System of Patients With Early HIV Disease

HIV Infections Clinical Trial

Official title:

Phase II Study of Cyclosporin (Neoral) in Immune Activation and HIV Expression in Early HIV Disease

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00000880
• Other study ID #: ACTG 334
• Secondary ID: 11306
• Status: Completed
• Phase: Phase 2
• Est. completion date: May 2000

Study information

• Verified date: October 2021
• Source: National Institute of Allergy and Infectious Diseases (NIAID)
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine the safety and effectiveness of low doses of cyclosporine (CsA) in patients with early HIV infection and to evaluate its effect on the immune system.

Activation of T cells (cells of the immune system) leads to HIV replication. Inhibition of immune activation is therefore a potentially important area of therapy for patients with early HIV infection. CsA is capable of decreasing T cell activation, which in turn may decrease HIV replication.

Description:

There is increasing data on the potential for inhibition of immune activation as primary therapy for HIV infection. The rationale of CsA therapy is to decrease T cell activation in patients with early HIV infection. Activation of T cells leads to translation and transcription of provirus, release of viral progeny, and ultimately cell death. T cell activation also leads to increased cell death via apoptosis. CsA is capable of inhibiting both these events and thus may lead to decreased CD4 cell turnover.

This study has 2 arms of 15 patients each. Patients in Arm I receive placebo. Patients in Arm II receive CsA. Each arm is further divided into 2 strata. Stratum 1 patients are not allowed to receive antiretroviral therapy. Stratum 2 patients must receive 1 of the following 4 stable nucleoside analogue combinations:

1. Zidovudine (ZDV) plus lamivudine (3TC)

2. ZDV plus didanosine (ddI)

3. Stavudine (d4T) plus 3TC

4. d4T plus ddI.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: May 2000
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria

You may be eligible for this study if you:

• Are HIV-positive.

• Have a CD4 count greater than or equal to 500/mm3.

• Have a plasma HIV RNA level greater than 600 copies/ml.

• Are over 18 years of age.

• Agree to practice abstinence or use barrier methods of birth control during the study.

Exclusion Criteria

You will not be eligible for this study if you:

• Have a history of an AIDS-defining illness, autoimmune disease, or hypertension.

• Have renal disease.

• Have any active infection other than HIV.

• Have used certain antiretroviral medications.

• Are pregnant.

Related Conditions & MeSH terms

• Acquired Immunodeficiency Syndrome
• HIV Infections

Intervention

Drug:
• Cyclosporine

Locations

Country	Name	City	State
United States	Johns Hopkins Hosp	Baltimore	Maryland
United States	Harvard (Massachusetts Gen Hosp)	Boston	Massachusetts
United States	Univ of North Carolina	Chapel Hill	North Carolina
United States	Northwestern Univ Med School	Chicago	Illinois
United States	Rush Presbyterian - Saint Luke's Med Ctr	Chicago	Illinois
United States	Case Western Reserve Univ	Cleveland	Ohio
United States	Univ of Colorado Health Sciences Ctr	Denver	Colorado
United States	Univ of Texas Med Branch	Galveston	Texas
United States	Bellevue Hosp / New York Univ Med Ctr	New York	New York
United States	Beth Israel Med Ctr	New York	New York
United States	San Francisco Gen Hosp	San Francisco	California
United States	Univ of Washington	Seattle	Washington

Sponsors (1)

Lead Sponsor	Collaborator
National Institute of Allergy and Infectious Diseases (NIAID)

Country where clinical trial is conducted

United States, 

References & Publications (1)

Calabrese LH, Lederman MM, Spritzler J, Coombs RW, Fox L, Schock B, Yen-Lieberman B, Johnson R, Mildvan D, Parekh N; AIDS Clinical Trials Group 334 Investigators. Placebo-controlled trial of cyclosporin-A in HIV-1 disease: implications for solid organ transplantation. J Acquir Immune Defic Syndr. 2002 Apr 1;29(4):356-62. — View Citation